Stroke-related Pneumonia
Conditions
Keywords
Stroke-related pneumonia, micropopulation
Brief summary
This study intends to use a standardized cohort study to collect biological samples (including throat swabs, sputum and blood) from subjects eligible for inclusion, and use 16s DNA / metagenomic sequencing and metabolome technology to explore the microbial-host interaction relationship of SAP patients.
Detailed description
Stroke-related pneumonia (SAP) is the most common complication of acute cerebral hemorrhage, and it is one of the main causes of disease aggravation, prolonged hospitalization and costs, and even death. The traditional antibiotic model proved ineffective, and new prevention and treatment methods were urgently sought.This study intends to use a standardized and rigorous cohort study to collect biological samples (including throat swabs, sputum and blood) of eligible subjects, and to explore the microbial-host interaction relationship in patients with SAP, which may provide new targets and new ideas for the prevention and control of SAP.
Interventions
None listed
Sponsors
Guangzhou University of Traditional Chinese Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age: 18 years old; * Stroke was confirmed by imaging; * Within 48 hours of onset, the onset time cannot be determined from the last normal observation; * Glasgow Coma Scale (GCS) 7-14; * SAP by clinical symptoms, laboratory examination or imaging confirmation, the modified CDC diagnostic criteria; * The patient (or his / her legal representative) signs a written informed consent form.
Exclusion criteria
* Use of antibiotics within 4 weeks before stroke onset; * The presence of other conditions that may interfere with the follow-up and outcome assessment (such as known significant prestroke disability, mRS score of 3-5, end-stage malignancy, and liver and renal failure); * Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the microbiota in throat swabs and sputum | baseline, 3 days, 7 days, 14 days after enrollment, or at discharge | Microbiota changes in each set of throat swabs and sputum will be examined using 16s DNA / metagenome sequencing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Barthel-Index (BI) | 90 days after enrollment | BI values range from 0-100: The higher the score, the better the result. |
| Changes in the blood plasma metabolites | baseline, 3 days, 7 days, 14 days after enrollment, or at discharge | Ultra HPLC-tandem mass spectrometry will be used to test plasma metabolite expression in each group. |
| Utility-weighted modified Rankin scale score | 90 days after enrollment | Utility-weighted modified Rankin scale score. Values range from 0 to 10: The higher the score, the better the result. |
| The European Quality of Life 5-Dimensional Questionnaire (EQ-5D-5L) | 90 days after enrollment | The EQ-5D includes five dimensions of health: mobility, self-care, ability to perform daily activities, pain and discomfort, and anxiety and depression. EQ-5D-5L, including five severity levels (none, minor, moderate, severe, serious, and extreme). Value range 0-100: The higher the score, the worse the result. |
Contacts
Primary ContactJianwen Guo, Dr
Backup ContactDou Wang, Dr
Outcome results
None listed